Bridging the Gap: The Crucial Role of Private Healthcare in Achieving Universal Health Coverage

By Staff Writer

September 1, 2023

The World Bank Group (2017) estimates that at least half of the world’s population lacks access to basic healthcare. Moreover, nearly 100 million people are plunged into poverty annually due to healthcare expenses. These gaps in health provision are notably severe in low-income countries (LICs), where the majority of those facing impoverishing health expenses reside.

Universal Health Coverage (UHC) – defined as the global aim to ensure everyone receives the health services they need without suffering financial hardship – has been proposed as a solution to this pressing issue. The World Health Organisation (WHO) conceptualizes UHC as a ‘cube’ comprising three key dimensions: population coverage, service coverage, and financial risk protection.


Source: Authors’ own elaboration, adapted from Kutsin (2013) and the WHO UHC cube (World Health Organisation, 2010; Kutzin, 2013).

However, the role of private healthcare in achieving UHC remains a subject of ongoing debate. While the public and private health sectors interact and shape each other’s performance, the unclear boundaries between the two make it difficult to define a UHC role for the private sector.

Private-for-profit (PFP) providers, motivated by commercial interests, and private not-for-profits (PNFPs), usually driven by philanthropic motives, are the two main types of private healthcare providers. The central role of profit in PFPs has ignited debate on their ability to adequately serve the poor and whether they can be contracted by governments to advance UHC goals.

The informal sector in LICs, which includes traditional birth attendants and healers, unlicensed drug shops, and market stalls, provides a substantial proportion of healthcare, particularly for the poor. However, the quality of care in both the public and private sectors in LICs often falls short, particularly at the lower end of the market.

A recent study extends the debate on the role of private healthcare in LICs by systematically reviewing recently published literature. They found that while formal private providers typically operate in already well-served urban settings, informal and not-for-profit ones cater to patients in underserved rural areas and generally at the lower end of the health market.

However, improving the quality and financing of informal providers may be key to expanding UHC in LICs. Given their ubiquitous nature and diversity of contributions, mechanisms for (self) accreditation will need to be strengthened to guarantee a minimum level of service quality from these actors.

Quality and effectiveness should be considered core principles of universal coverage and represent an additional dimension of the UHC cube in its own right.

Reference url

Recent Posts

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

value-based drug pricing
      

Optimizing Value-Based Drug Pricing in Japan with MARIE Framework

🔍 Are we pricing drugs based on true value?

The introduction of the MARIE framework in Japan revolutionizes value-based drug pricing by considering not just costs, but the actual benefits drugs provide to patients and society. This innovative approach significantly adjusts prices based on updated clinical data and allows for more equitable access to therapies.

Curious about how MARIE can reshape drug pricing and pharmaceutical innovation? Dive into the full article for insights!

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.